Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HitGenSHSE:688222 +3.04%90 PB Ratio is 7.60 as of Jul. 23, 2026, which is 41% above its 10-year median of 5.40. GuruFocus rates SHSE:688222 with a GF Score™ of 90/100 and a GF Value™ of ¥26.07 (Modestly Overvalued). The stock has 1 warning sign investors should review. Among 1,230 Biotechnology companies, HitGen ranks worse than 80.24% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-23), HitGen's share price is ¥29.16. HitGen's Book Value per Share for the quarter that ended in Mar. 2026 was ¥3.84. Hence, HitGen's PB Ratio of today is 7.60.
The historical rank and industry rank for HitGen's PB Ratio or its related term are showing as below:
SHSE:688222'
s PB Ratio Range Over the Past 10 Years
Min: 2.52 Med: 5.4 Max: 41.26
Current: 7.59
During the past 10 years, HitGen's highest PB Ratio was 41.26. The lowest was 2.52. And the median was 5.40.
SHSE:688222's PB Ratio is ranked worse than 80.24% of 1230
companies
in the Biotechnology industry
Industry Median: 2.82
vs SHSE:688222: 7.59
During the past 12 months, HitGen's average Book Value Per Share Growth Rate was 8.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 4.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 3.00% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of HitGen was 129.20% per year. The lowest was 1.90% per year. And the median was 31.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
HitGen PB Ratio Related Terms
HitGen PB Ratio Historical Data
* Premium members only.
The historical data trend for HitGen's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688222 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, HitGen's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HitGen PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HitGen's PB Ratio distribution charts can be found below:
* The bar in red indicates where HitGen's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
HitGen's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
HitGen (SHSE:688222) has a PB Ratio of 7.60 as of Jul. 23, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HitGen and its competitors. This is 41% above median its historical median of 5.40. Over the past decade, HitGen's PB Ratio has ranged from 2.52 to 41.26. According to the industry distribution chart, HitGen ranks #987 out of 1230 companies in the Biotechnology industry, placing it in the top 80.2%.
Is HitGen's PB Ratio too high?
HitGen's current PB Ratio of 7.60 is 41% above median its 10-year median of 5.40. Over the past 10 years, this metric has ranged from a low of 2.52 to a high of 41.26. The Biotechnology industry median PB Ratio is 2.82. HitGen's value of 7.60 is 169.5% above this industry median. Based on the distribution chart, HitGen ranks #987 out of 1230 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, HitGen has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does HitGen's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HitGen ranks #987 out of 1230 companies for PB Ratio. This places HitGen in the lower half of its industry. The industry median PB Ratio is 2.82. HitGen's value of 7.60 is 169.5% above this benchmark. Historically, HitGen's own PB Ratio has ranged from 2.52 to 41.26 over the past decade. While the company's 10-year median is 5.40 vs. the industry median of 2.82, HitGen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.82, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HitGen's current PB Ratio of 7.60 is 169.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on HitGen and its competitors. For the Biotechnology industry, the median PB Ratio is 2.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HitGen's current PB Ratio is 7.60, which is 41% above median its own 10-year median of 5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HitGen stock overvalued right now?
Based on GuruFocus' analysis, HitGen (SHSE:688222) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥26.07, compared to a current price of ¥29.16 — trading 11.9% above its estimated fair value. The current PB Ratio is 7.60, which is 41% above median its 10-year median of 5.40 and 169.5% above the Biotechnology industry median of 2.82. HitGen's overall GF Score™ is 90/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For HitGen (SHSE:688222), the current PB Ratio is 7.60 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HitGen (SHSE:688222) Overvalued in 2026?
Based on GuruFocus' analysis, HitGen stock appears to be overvalued.
The current stock price of ¥29.16 is trading 11.9% above its estimated GF Value™ of ¥26.07.
GuruFocus considers HitGen to be Modestly Overvalued.
Key valuation signals for SHSE:688222:
PB Ratio: 7.60 (41% above median its 10-year median of 5.40)
GF Value™: ¥26.07 vs. price of ¥29.16 (11.9% above fair value)
Industry Position: 169.5% above the Biotechnology median (#987 of 1230)
No single metric tells the full story. See the SHSE:688222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HitGen Inc is dedicated to building a world-class biopharmaceutical enterprise. Its mission is to advance human health and quality of life. It provides therapeutic solutions to address unmet medical needs. Centered on its internationally DEL (DNA-encoded Library) technology, the Company has expanded into Fragment-Based Drug Discovery and Structure-Based Drug Design and a suite of complementary platforms based on Oligonucleotide-based Therapeutics, Targeted Proximity Drugs, and Cyclic Peptidomimetics. The group has developed HAILO, a proprietary "DEL+AI+Automation" molecular optimization platform, thereby establishing a distinctive novel molecule discovery engine that delivers both therapeutic molecules and tool molecules to the world-wide pharmaceutical industry.
90GF Score
Get the complete analysis for SHSE:688222
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688222 has been successfully added to your 
